Mephenon

Methadone Hydrochloride, the active ingredient in Mephenon, is an opioid agonist presented as an injectable solution for intramuscular; intravenous use. It treats severe chronic pain and helps manage opioid dependence and withdrawal in adult patients. GNH USA supplies Mephenon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone Hydrochloride is an opioid agonist used in pain management and opioid dependence treatment.

- Severe chronic pain: provides long‑acting analgesia for patients with persistent severe pain. - Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Opioid detoxification: facilitates gradual tapering of opioid use during supervised withdrawal programs.

Methadone Hydrochloride may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Sweating: excessive perspiration unrelated to temperature. - Dizziness: sensation of light‑headedness or unsteadiness. - Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - QT interval prolongation: cardiac electrical disturbance that may cause arrhythmia. - Severe hypotension: marked drop in blood pressure leading to fainting. - Cardiac arrhythmia: irregular heart rhythm requiring immediate medical attention. - Adrenal insufficiency: inadequate production of adrenal hormones. - Seizures: uncontrolled electrical activity in the brain.

When using Methadone Hydrochloride, clinicians should observe several safety measures.

- Respiratory assessment: monitor breathing rate and oxygen saturation, especially during initiation. - Cardiac monitoring: obtain baseline ECG and watch for QT prolongation. - Hepatic function: adjust dosing in patients with liver impairment. - Concomitant CNS depressants: avoid or use with caution to reduce risk of respiratory depression. - Gradual tapering: discontinue only under medical supervision to prevent withdrawal. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methadone Hydrochloride interacts with several drug classes; careful management is required.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, alcohol): may cause profound respiratory depression. - Monoamine oxidase inhibitors: can precipitate severe hypotension or serotonin syndrome. - QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise methadone plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce methadone effectiveness. - Selective serotonin reuptake inhibitors: require monitoring for additive serotonergic effects.